Treatment With Tocilizumab for Patients With COVID-19 Infections: A Case-Series Study

Area of Science:

• Immunology
• Infectious Diseases
• Pharmacology

Background:

• Interleukin-6 receptor inhibition with Tocilizumab (TCZ) is a potential treatment for severe COVID-19.
• Cytokine storm syndrome is a serious complication of COVID-19.
• Limited data exists on TCZ's clinical impact in COVID-19 patients.

Purpose of the Study:

• To evaluate the safety and effectiveness of TCZ as an adjunct therapy for severe COVID-19.
• To assess TCZ's impact on vital signs, laboratory biomarkers, and clinical outcomes.

Main Methods:

• Retrospective observational chart review of 38 confirmed COVID-19 patients treated with TCZ.
• Analysis of changes in temperature, C-reactive protein, duration of mechanical ventilation, and length of stay.
• Monitoring for adverse events, including infections and elevated liver enzymes.

Main Results:

• Median C-reactive protein significantly decreased post-TCZ administration (189.9 to 54.8 mg/L, P = .003).
• 73% of febrile patients became fever-free by day four of TCZ treatment.
• Adverse events included multidrug-resistant bacterial infections (11 patients) and elevated liver transaminases (6 patients).

Conclusions:

• TCZ appears to ameliorate COVID-19-related cytokine storm syndrome.
• TCZ demonstrated potential in reducing key inflammatory markers and fever in severe COVID-19 patients.
• Further large randomized controlled trials are necessary to confirm TCZ's efficacy and safety in COVID-19 treatment.